Webinar: A Quick Guide to IVIVC Testing
Accelerating time to market and adopting better practice in the development, manufacture and quality assurance of medicines are ongoing goals for the pharmaceutical industry.
Better IVIVCs have long been an industry aim, but the current climate clearly adds impetus to the desire for progress. Inhaled product development in particular presents some unique challenges in this respect. The difficulty of precisely correlating drug deposition behaviour with clinical efficacy, the impact of patient-to-patient variability and the complex interaction between formulation and device, all complicate the development process.
This webinar will cover the basics of inhaled product IVIVC testing and will examine the difficulties and challenges that analysts might face.
If you have any specific questions about IVIVC testing, you can ask the Copley team directly during the webinar, using the interactive Q&A chat box.
About the Presenter
Anna Sipitanou, MSc | Business Development Manager
Anna holds a BSc in Chemistry and an MSc in Drug Discovery & Pharmaceutical Sciences. Having joined Copley Scientific in 2017, Anna plays a key role in the company’s technical and sales support services, including the training of customers on a wide range of pharmaceutical testing equipment, with a particular focus on OINPD testing. Having worked closely with pharmaceutical companies on a wide range of OINDP projects, Anna has gained specialist knowledge of the regulatory requirements for both delivered dose uniformity (DDU) and aerodynamic particle size distribution (APSD) testing, as well as extensive experience in methods to improve in-vitro-in-vivo correlations (IVIVC) and other specialist testing applications, including generic drug development, inhaled dissolution and facemask testing.